Alto Neuroscience, Inc. Common Stock (NY:ANRO)

24.37 +0.34 (+1.41%)

Official Closing Price Updated: 7:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

September 09, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

August 27, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 12, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

July 13, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

June 15, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

May 28, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

May 15, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

May 11, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting

May 04, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

April 21, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements

April 01, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces $120 Million Private Placement Financing

March 16, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

March 16, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

March 13, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

February 23, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia

February 13, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment

February 03, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression

January 14, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology

January 13, 2026

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08

December 03, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 12, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience to Participate in Upcoming Investor Conferences

October 28, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces $50 Million Private Placement Financing

October 20, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

October 20, 2025

From Alto Neuroscience, Inc.

Via Business Wire

ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

October 07, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

October 03, 2025

From Alto Neuroscience, Inc.

Via Business Wire

Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf

September 22, 2025

From Grabar Law Office

Via GlobeNewswire

Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO

September 19, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO

September 19, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.